About Spiration®
Spiration is committed to improving quality of life for patients with acute and chronic conditions of the lung through the development of novel therapies. Founded in 1999 in Redmond, Wash., Spiration is a pioneer in its field, with 26 issued US patents addressing various conditions of the lung.
Spiration’s IBV® Valve System is a minimally invasive device which has received market clearance through CE Mark for treatment of diseased and damaged lung in Europe.
The IBV® Valve System has received Humanitarian Device Exemption (HDE) Approval in the U.S. to control prolonged air leaks of the lung or significant air leaks that are likely to become prolonged following lobectomy, segmentectomy or lung volume reduction surgery.
The IBV® Valve System is under investigation in the U.S. as a new treatment option for patients with severe emphysema. The IBV® Valve System is also an investigational device in Canada.
Spiration has raised approximately $97 million to date from prominent investors including Three Arch Partners, New Enterprise Associates, Versant Ventures, Sprout Group, InterWest Partners, Investor Growth Capital, GE Capital, Saints Capital and Olympus Medical Systems Corporation.